#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Adolescents with cannabis use disorder face increasing treatment delays, which can worsen substance use trajectories, co-occurring mental health conditions, and long-term outcomes during a critical developmental period. Clinicians need to understand this access gap to advocate for adequate treatment resources, screen more proactively for cannabis use disorder in teen populations, and implement evidence-based interventions when delays occur. For patients, these delays represent missed opportunities for early intervention when outcomes are most responsive to treatment.
A recent analysis of over 124,000 adolescent treatment admissions published in the American Journal of Preventive Medicine reveals a concerning trend of increasing treatment delays for teenagers diagnosed with cannabis use disorder. The study found that a growing proportion of adolescents with cannabis use disorder are experiencing significant waits before accessing specialized treatment services, suggesting capacity constraints in the adolescent addiction treatment infrastructure. These delays are particularly relevant for clinicians managing young patients with cannabis dependence, as prolonged waiting periods may worsen psychiatric comorbidities, academic outcomes, and the severity of substance use patterns during the critical developmental window of adolescence. The findings underscore a critical gap between rising demand for adolescent cannabis use disorder treatment and available treatment capacity in publicly funded systems. Clinicians should be aware of these system-level barriers when counseling adolescent patients and families, and may need to explore alternative interventions or private treatment options while their patients await publicly funded care. Healthcare systems and policymakers must prioritize expanding adolescent addiction treatment capacity to prevent the harmful consequences associated with treatment delays.
“What we’re seeing in the treatment-access data is concerning but not surprising given current resource constraints, and it underscores why we need to invest in adolescent-focused cannabis use disorder services before the clinical consequences of these delays become even more apparent.”
🧠 Rising treatment delays for adolescent cannabis use disorder highlight a significant gap between clinical need and care access that warrants attention in primary and specialty settings. While the study’s use of national admission data provides robust epidemiologic insights, clinicians should recognize that treatment delays may reflect multiple confounding factors including insurance barriers, geographic disparities, workforce shortages in adolescent addiction medicine, and variations in screening practices across settings rather than purely clinical considerations. The clinical relevance is substantial: prolonged intervals between disorder onset and treatment initiation are associated with worse developmental trajectories, increased psychiatric comorbidity, and higher relapse rates in this vulnerable population. Healthcare providers should consider proactive screening for cannabis use disorder in routine adolescent visits and maintain updated referral networks to addiction specialists, recognizing that even modest reductions in treatment delay may improve long-term outcomes. Given current access constraints, clinicians may need to leverage telehealth, integrated care models, and brief interventions
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
